AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$32.40
arrow_downward
-4.37%(-1.48) 1D
$32.40
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 9, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMLX...
Open
$33.50
High
$34.35
Low
$32.30
Mkt. cap
4.06B
Avg. vol.
3.29M
Volume
0.00
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.13
Shares outstanding
125.51M
No. of employees
136
Open
$33.50
High
$34.35
Low
$32.30
Mkt. cap
4.06B
Avg. vol.
3.29M
Volume
0.00
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.13
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
Simply Wall Street
·
6 hours ago
How Supply Deals At Amylyx Pharmaceuticals (AMLX) Have Changed Its Investment Story
Stock Titan
·
18 hours ago
After two decades at Alkermes, a biotech CFO joins Tortugas’ board
TipRanks
·
1 day ago
Amylyx inks long-term manufacturing deal for avexitide
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc